VIATRIS INC. Payments of Financing Costs
VIATRIS INC. (VTRS) reported Payments of Financing Costs of $3.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2026-08-06
- VIATRIS INC. payments of financing costs for the quarter ending 2025-12-31 was $200.00K.
- VIATRIS INC. payments of financing costs for the quarter ending 2025-09-30 was $300.00K, a 93.75% decline year-over-year.
- VIATRIS INC. payments of financing costs for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- VIATRIS INC. payments of financing costs for the quarter ending 2024-09-30 was $4.80M, a 1500.00% increase year-over-year.
- VIATRIS INC. payments of financing costs for fiscal 2025 was $1.50M, a 68.75% decline from fiscal 2024.
- VIATRIS INC. payments of financing costs for fiscal 2024 was $4.80M, a 860.00% increase from fiscal 2023.
- VIATRIS INC. payments of financing costs for fiscal 2023 was $500.00K, a 73.68% decline from fiscal 2022.
- VIATRIS INC. payments of financing costs for fiscal 2022 was $1.90M, a 72.86% decline from fiscal 2021.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.00M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $500.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.50M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.30M 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $1.00M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.80M derived: sum of 2 quarters · filed 2026-02-26 | $4.80M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $4.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.80M 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | |||
| 2023-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $500.00K derived: sum of 2 quarters · filed 2026-02-26 | $500.00K derived: sum of 3 quarters · filed 2026-02-26 | $500.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $300.00K derived: sum of 2 quarters · filed 2024-11-07 | $300.00K 10-Q · filed 2024-11-07 | $600.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | $300.00K derived: sum of 3 quarters · filed 2025-02-27 | $600.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-08 | $300.00K derived: sum of 2 quarters · filed 2025-02-27 | $600.00K derived: sum of 3 quarters · filed 2025-02-27 | $1.50M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $600.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.50M derived: sum of 3 quarters · filed 2025-02-27 | $1.90M 10-K · filed 2025-02-27 |
| 2022-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.20M derived: sum of 2 quarters · filed 2023-11-08 | $1.60M 10-Q · filed 2023-11-08 | $2.10M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $900.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $1.30M 10-Q · filed 2023-08-07 | $1.80M derived: sum of 3 quarters · filed 2024-02-28 | $8.10M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $400.00K 10-Q · filed 2023-05-08 | $900.00K derived: sum of 2 quarters · filed 2024-02-28 | $7.20M derived: sum of 3 quarters · filed 2024-02-28 | $7.40M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $6.80M derived: sum of 2 quarters · filed 2024-02-28 | $7.00M derived: sum of 3 quarters · filed 2024-02-28 | $7.00M 10-K · filed 2024-02-28 |
| 2021-09-30 | $6.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $6.50M derived: sum of 2 quarters · filed 2022-11-07 | $6.50M 10-Q · filed 2022-11-07 | $6.70M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $200.00K 10-Q · filed 2022-08-08 | $400.00K derived: sum of 3 quarters · filed 2023-02-27 | $1.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-09 | $200.00K derived: sum of 2 quarters · filed 2023-02-27 | $800.00K derived: sum of 3 quarters · filed 2023-02-27 | |
| 2020-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $800.00K derived: sum of 2 quarters · filed 2023-02-27 | $2.00M 10-K · filed 2023-02-27 | |
| 2020-09-30 | $600.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $1.80M 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | $1.20M 10-Q · filed 2021-08-09 | |||
| 2019-12-31 | $3.00M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $21.40M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |